Open AccessRetapamulin: A newer topical antibiotic
Author(s) -
Dhulika Dhingra,
Ankit Parakh,
Smita Ramachandran
Publication year - 2013
Publication title -
journal of postgraduate medicine/journal of postgraduate medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.405
H-Index - 52
eISSN - 0972-2823
pISSN - 0022-3859
DOI - 10.4103/0022-3859.113842
Subject(s) - impetigo , medicine , mupirocin , fusidic acid , antibiotics , staphylococcus aureus , dermatology , drug , bacitracin , potency , skin infection , drug resistance , pharmacology , microbiology and biotechnology , methicillin resistant staphylococcus aureus , bacteria , biochemistry , chemistry , biology , in vitro , genetics
Impetigo is a common childhood skin infection. There are reports of increasing drug resistance to the currently used topical antibiotics including fusidic acid and mupirocin. Retapamulin is a newer topical agent of pleuromutilin class approved by the Food and Drug Administration for treatment of impetigo in children and has been recently made available in the Indian market. It has been demonstrated to have low potential for the development of antibacterial resistance and a high degree of potency against poly drug resistant Gram-positive bacteria found in skin infections including Staphylococcus aureus strains. The drug is safe owing to low systemic absorption and has only minimal side-effect of local irritation at the site of application.